<p>CureVac N.V.（納斯達克代碼：CVAC - 獲取免費報告）在七月份的空頭頭寸大幅下降。截至 7 月 31 日，空頭頭寸總計 741,700 股，比 7 月 15 日的 1,060,000 股下降了 30.0%。該股票約有 0.8% 的股份被做空。根據平均交易量 1,210,000 股，目前的覆蓋天數比率為 0.6 天。</p>
<h2>CureVac 價格表現</h2>
<ul>
<li>2 只小盤股在牛市中有望大放異彩</li>
</ul>
<p>納斯達克 CVAC 週三開盤價為 5.46 美元。該公司的 50 日簡單移動平均為 5.42 美元，200 日簡單移動平均為 4.11 美元。CureVac 的 52 周低點為 2.37 美元，52 周高點為 5.72 美元。該公司的債務與股本比率為 0.05，速動比率為 7.64，流動比率為 6.17。該股票的市值為 12.2 億美元，市盈率為 5.69，貝塔值為 2.53。</p>
<p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近於 8 月 21 日發佈了季度財報。該公司報告本季度每股收益為（0.30 美元），低於分析師一致預期的（0.15 美元）15 美分。CureVac 的股本回報率為 29.57%，淨利潤率為 38.21%。該公司本季度的收入為 141 萬美元，而分析師預期為 427 萬美元。分析師預計 CureVac 在當前財政年度的每股收益為 0.72 美元。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>3 只股票適合在 COVID 復甦中購買</li>
</ul>
<p>CVAC 成為多份研究分析師報告的主題。Citizens JMP 在 6 月 12 日的報告中將 CureVac 的評級從 “強烈買入” 下調至 “持有”。瑞銀集團在 6 月 26 日的研究報告中將 CureVac 的股票評級從 “強烈買入” 下調至 “中性”，並將其目標價從 12.00 美元下調至 5.50 美元。花旗集團在 6 月 12 日的研究報告中將 CureVac 的股票評級下調至 “市場表現”。JMP 證券在 5 月 28 日的報告中重申了 “市場跑贏大盤” 的評級，並對 CureVac 的股票設定了 10.00 美元的目標價。最後，傑富瑞金融集團在 6 月 13 日的研究報告中重新發布了 “持有” 評級，並將 CureVac 的目標價設定為 5.00 美元（之前為 7.00 美元）。一位股票研究分析師對該股票給予了買入評級，四位分析師給予了持有評級。根據 MarketBeat，該公司目前的共識評級為 “持有”，共識目標價為 6.83 美元。</p>
<p><strong>閲讀我們對 CureVac 的最新分析</strong></p>
<h2>機構資金流入與流出</h2>
<p>一些機構投資者和對沖基金最近增加或減少了對 CVAC 的持股。Alpine Associates Management Inc.在第二季度購買了 CureVac 的新股份，價值為 10,703,000 美元。Qube Research &amp; Technologies Ltd 在第二季度獲得了 CureVac 的新頭寸，價值為 6,419,000 美元。Water Island Capital LLC 在第二季度獲得了 CureVac 的新頭寸，價值為 5,197,000 美元。摩根大通在第二季度獲得了 CureVac 的新頭寸，價值為 1,705,000 美元。最後，GSA Capital Partners LLP 在第一季度獲得了 CureVac 的新頭寸，價值為 853,000 美元。17.26% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 CureVac</h2>
<p>（獲取免費報告）</p>
<p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，處於第一階段臨牀試驗；以及 CVSQIV 用於治療多價季節性流感；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過 CureVac</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Archer 的飛行里程碑和防禦勝利令華爾街興奮</li>
<li>TSX 風險投資交易所（前加拿大風險投資交易所）</li>
<li>Upstart 股票可能會因短期擠壓而上漲</li>
<li>如何從成長投資中獲利</li>
<li>這隻鐵路股票正在向新的歷史高點邁進</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CureVac 嗎？</h2>
<p>在考慮 CureVac 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
<p>雖然 CureVac 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CVAC

<p>CureVac N.V.（納斯達克代碼：CVAC）在短期空頭頭寸方面經歷了顯著下降，7 月份下降了 30.0%，降至 741,700 股。這代表了公司被賣空股份的 0.8%，根據 121 萬股的平均交易量，短期空頭頭寸比率為 0.6 天。該股票開盤價為 5.46 美元，市值為 12.2 億美元，市盈率為 5.69。分析師的評級意見不一，普遍評級為 “持有”，目標價為 6.83 美元。機構投資者持有該股票的 17.26%</p>

<p>CureVac N.V. (NASDAQ:CVAC - Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 741,700 shares, adropof30.0% from the July 15th total of 1,060,000 shares. Approximately0.8% of the shares of the stock are short sold. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately0.8% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>CureVac N.V.（納斯達克代碼：CVAC - 獲取免費報告）在七月份的空頭頭寸大幅下降。截至 7 月 31 日，空頭頭寸總計 741,700 股，比 7 月 15 日的 1,060,000 股下降了 30.0%。該股票約有 0.8% 的股份被做空。根據平均交易量 1,210,000 股，目前的覆蓋天數比率為 0.6 天。</p>
</div><h2>CureVac Price Performance</h2>
<div class="lb-trans"><h2>CureVac 價格表現</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盤股在牛市中有望大放異彩</li>
</ul>
</div><p>NASDAQ CVAC opened at $5.46 on Wednesday. The business has a 50 day simple moving average of $5.42 and a 200 day simple moving average of $4.11. CureVac has a 52-week low of $2.37 and a 52-week high of $5.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.64 and a current ratio of 6.17. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 5.69 and a beta of 2.53.</p>
<div class="lb-trans"><p>納斯達克 CVAC 週三開盤價為 5.46 美元。該公司的 50 日簡單移動平均為 5.42 美元，200 日簡單移動平均為 4.11 美元。CureVac 的 52 周低點為 2.37 美元，52 周高點為 5.72 美元。該公司的債務與股本比率為 0.05，速動比率為 7.64，流動比率為 6.17。該股票的市值為 12.2 億美元，市盈率為 5.69，貝塔值為 2.53。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. Analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近於 8 月 21 日發佈了季度財報。該公司報告本季度每股收益為（0.30 美元），低於分析師一致預期的（0.15 美元）15 美分。CureVac 的股本回報率為 29.57%，淨利潤率為 38.21%。該公司本季度的收入為 141 萬美元，而分析師預期為 427 萬美元。分析師預計 CureVac 在當前財政年度的每股收益為 0.72 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票適合在 COVID 復甦中購買</li>
</ul>
</div><p>CVAC has been the subject of a number of research analyst reports. Citizens Jmp lowered CureVac from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, June 12th. UBS Group downgraded shares of CureVac from a &#34;strong-buy&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the stock from $12.00 to $5.50 in a research note on Thursday, June 26th. Citigroup downgraded shares of CureVac to a &#34;market perform&#34; rating in a research note on Thursday, June 12th. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $10.00 price objective on shares of CureVac in a report on Wednesday, May 28th. Finally, Jefferies Financial Group reissued a &#34;hold&#34; rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $6.83.</p>
<div class="lb-trans"><p>CVAC 成為多份研究分析師報告的主題。Citizens JMP 在 6 月 12 日的報告中將 CureVac 的評級從 “強烈買入” 下調至 “持有”。瑞銀集團在 6 月 26 日的研究報告中將 CureVac 的股票評級從 “強烈買入” 下調至 “中性”，並將其目標價從 12.00 美元下調至 5.50 美元。花旗集團在 6 月 12 日的研究報告中將 CureVac 的股票評級下調至 “市場表現”。JMP 證券在 5 月 28 日的報告中重申了 “市場跑贏大盤” 的評級，並對 CureVac 的股票設定了 10.00 美元的目標價。最後，傑富瑞金融集團在 6 月 13 日的研究報告中重新發布了 “持有” 評級，並將 CureVac 的目標價設定為 5.00 美元（之前為 7.00 美元）。一位股票研究分析師對該股票給予了買入評級，四位分析師給予了持有評級。根據 MarketBeat，該公司目前的共識評級為 “持有”，共識目標價為 6.83 美元。</p>
</div><p><strong>Read Our Latest Analysis on CureVac</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 CureVac 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVAC. Alpine Associates Management Inc. bought a new stake in shares of CureVac during the 2nd quarter valued at $10,703,000. Qube Research &amp; Technologies Ltd acquired a new position in shares of CureVac during the 2nd quarter worth $6,419,000. Water Island Capital LLC acquired a new position in shares of CureVac during the 2nd quarter worth $5,197,000. JPMorgan Chase &amp; Co. acquired a new position in shares of CureVac during the 2nd quarter worth $1,705,000. Finally, GSA Capital Partners LLP acquired a new position in shares of CureVac during the 1st quarter worth $853,000. 17.26% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近增加或減少了對 CVAC 的持股。Alpine Associates Management Inc.在第二季度購買了 CureVac 的新股份，價值為 10,703,000 美元。Qube Research &amp; Technologies Ltd 在第二季度獲得了 CureVac 的新頭寸，價值為 6,419,000 美元。Water Island Capital LLC 在第二季度獲得了 CureVac 的新頭寸，價值為 5,197,000 美元。摩根大通在第二季度獲得了 CureVac 的新頭寸，價值為 1,705,000 美元。最後，GSA Capital Partners LLP 在第一季度獲得了 CureVac 的新頭寸，價值為 853,000 美元。17.26% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About CureVac</h2>
<div class="lb-trans"><h2>關於 CureVac</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，處於第一階段臨牀試驗；以及 CVSQIV 用於治療多價季節性流感；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Archer's Flight Milestones &amp; Defense Wins Excite Wall Street</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Upstart Stock Could Pop on a Short Squeeze Soon</li>
<li>How to Profit From Growth Investing</li>
<li>This Railroad Stock Is Chugging Along to a New All-Time High</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 CureVac</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Archer 的飛行里程碑和防禦勝利令華爾街興奮</li>
<li>TSX 風險投資交易所（前加拿大風險投資交易所）</li>
<li>Upstart 股票可能會因短期擠壓而上漲</li>
<li>如何從成長投資中獲利</li>
<li>這隻鐵路股票正在向新的歷史高點邁進</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CureVac 嗎？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CureVac 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
</div><p>While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CureVac 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

CureVac N.V.（納斯達克股票代碼：CVAC）的空頭頭寸減少了 30.0%